The Impact of Wealth and Race on GLP-1 Outcomes in Diabetes and Weight Loss

GLP-1 treatments have become a critical tool in managing diabetes and supporting weight loss. However, not all patients benefit equally. Research reveals that wealth and race play significant roles in determining access to these medications, as well as the effectiveness of treatment outcomes. Socioeconomic barriers often limit who can afford or even access GLP-1 therapies, leaving underserved populations at a disadvantage.

This disparity raises important questions about healthcare equity, especially in an era where personalized medicine is becoming more prominent. Forian's recent study featured on The Evidence Base delves into the complex relationship between wealth, race, and treatment success, providing valuable insights into the broader implications for public health.

For a deeper exploration of how these factors shape patient outcomes, click below to read the full article on The Evidence Base.